Skip to Main Content

A sales rep for Grifols is accusing the Spanish drug maker of illegally marketing an expensive orphan drug and defrauding US health care programs in a whistleblower lawsuit that was unsealed in federal court.

In her complaint, Heather Murray contends that Grifols management deliberately attempted to widen the otherwise narrow market for a drug called Thrombate III, which is used to treat hereditary antithrombin deficiency, a condition in which people are at higher risk of developing blood clots. The ailment occurs in about 1 in every 2,000 to 3,000 individuals, according to government estimates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.